Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ARZERRA vs AFINITOR
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Ofatumumab is a fully human monoclonal antibody that binds specifically to the CD20 molecule on B lymphocytes, resulting in complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC) of CD20+ cells.
Inhibitor of mammalian target of rapamycin (m TOR), specifically the m TORC1 complex, by binding to the FKBP-12 protein, reducing cell proliferation, angiogenesis, and glucose uptake.
Treatment of chronic lymphocytic leukemia (CLL) refractory to fludarabine and alemtuzumab,Treatment of previously untreated CLL in combination with chlorambucil,Treatment of relapsed CLL in combination with fludarabine and cyclophosphamide
Advanced hormone receptor-positive, HER2-negative breast cancer in postmenopausal women in combination with exemestane after failure of letrozole or anastrozole,Progressive neuroendocrine tumors of pancreatic origin (PNET) in unresectable, locally advanced or metastatic disease,Advanced renal cell carcinoma (RCC) after failure of sunitinib or sorafenib,Subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex (TSC) in patients requiring therapeutic intervention but not amenable to curative resection
ARZERRA (ofatumumab) for chronic lymphocytic leukemia (CLL): Initial dose 300 mg IV, then 1 week later 2000 mg IV weekly for 6 doses, then 2000 mg IV every 4 weeks for up to 4 additional doses. For relapsed CLL: 300 mg IV followed by 1000 mg IV on day 8, then 1000 mg IV on day 15 and day 22 of cycle 1, then 1000 mg IV on day 1 of cycles 2-6 (28-day cycles). Premedicate with acetaminophen, antihistamine, and corticosteroid.
10 mg orally once daily for advanced breast cancer, neuroendocrine tumors, and renal cell carcinoma; 10 mg orally once daily for subependymal giant cell astrocytoma (SEGA) in adults; 5 mg/m^2 orally once daily for SEGA in pediatric patients (titrated to trough levels 5-15 ng/m L).
Mean terminal elimination half-life after first dose is approximately 14 days (range 7–21 days) and increases with repeated dosing due to target-mediated clearance saturation; at steady state, half-life is ~24 days.
Terminal elimination half-life: 30 hours (range 15–40 hours) in healthy subjects; increases to 40–70 hours in moderate hepatic impairment.
Ofatumumab is a monoclonal antibody; metabolism is not through typical cytochrome P450 pathways. Clearance involves catabolism to peptides and amino acids.
Substrate of CYP3A4; metabolized primarily by CYP3A4; also a substrate of P-glycoprotein (P-gp).
Arzerra (ofatumumab) is eliminated primarily via the reticuloendothelial system and catabolism; renal excretion is minimal (<1% of dose as intact antibody). Biliary/fecal excretion has not been characterized, but as a monoclonal antibody, it is not significantly excreted in urine or feces.
Primarily fecal (80%) and renal (5%) as unchanged drug and metabolites. Biliary excretion is significant.
As a monoclonal antibody, ofatumumab does not bind to plasma proteins; protein binding is negligible.
74% bound to plasma proteins (primarily albumin and α1-acid glycoprotein).
Volume of distribution (Vd) is approximately 2.5–4.5 L, approximating plasma volume; does not distribute extensively into tissues (not reported in L/kg, but typical for Ig G1 monoclonal antibodies ~0.1–0.2 L/kg).
Mean steady-state Vd: 342 L (approx. 4.9 L/kg in a 70 kg adult), indicating extensive tissue distribution.
Subcutaneous: ~60–70% absolute bioavailability; intravenous: 100%.
Oral bioavailability: approximately 16% (low due to P-glycoprotein efflux and first-pass metabolism); food reduces variability but does not alter AUC significantly.
No dose adjustment required for mild to moderate renal impairment (Cr Cl ≥30 m L/min). Not studied in severe renal impairment (Cr Cl <30 m L/min) or hemodialysis; use with caution.
No dose adjustment for mild to moderate renal impairment (Cr Cl >=30 m L/min). For severe renal impairment (Cr Cl <30 m L/min): reduce dose to 5 mg once daily. End-stage renal disease (Cr Cl <15 m L/min): use with caution, no specific recommendation.
No dose adjustment required for mild hepatic impairment (Child-Pugh A). Not studied in moderate to severe hepatic impairment (Child-Pugh B or C); use with caution.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose to 5 mg daily; Child-Pugh C: reduce dose to 2.5 mg daily, or consider alternate therapy.
Safety and efficacy in pediatric patients (<18 years) have not been established; no recommended dosing.
For SEGA: 5 mg/m^2 orally once daily, adjusted to achieve everolimus trough concentrations of 5-15 ng/m L. Dose adjustments per AUC or tolerability. Not approved for other indications in children.
No specific dose adjustment required for elderly patients. Clinical studies included patients ≥65 years; overall efficacy and safety similar to younger adults, but higher incidence of serious infections and cardiac events observed.
No specific dose adjustment; start at recommended adult dose. Monitor for increased risk of infections, stomatitis, and metabolic effects due to age-related decline in organ function.
Hepatitis B virus (HBV) reactivation can occur with ofatumumab, leading to fulminant hepatitis, hepatic failure, and death. Screen all patients for HBV infection before initiation. Monitor HBV carriers during and after treatment.
No black box warnings.
Infusion reactions (including anaphylaxis), prolonged cytopenias, progressive multifocal leukoencephalopathy (PML), intestinal obstruction, tumor lysis syndrome, and infections including hepatitis B reactivation.
Non-infectious pneumonitis,Infections (including opportunistic infections),Hypersensitivity reactions including anaphylaxis,Angioedema,Renal failure,Impaired wound healing,Metabolic effects (hyperglycemia, dyslipidemia),Myelosuppression,Immunosuppression leading to increased risk of infections,Cases of fatal hemorrhage in patients with history of bleeding,Radiation sensitization and recall reactions, especially in patients with previous radiation therapy,Increased risk of pneumocystis jirovecii pneumonia (PJP) and other opportunistic infections; consider prophylaxis,Avoid live vaccines
Known hypersensitivity (anaphylaxis) to ofatumumab or any of its excipients.
Hypersensitivity to everolimus, sirolimus, or any component of the formulation
No known food interactions. Take with or without food.
Avoid grapefruit, grapefruit juice, and Seville oranges (including marmalade) due to CYP3A4 inhibition increasing everolimus levels. Take consistently with or without food, but high-fat meals reduce absorption. Avoid St. John's wort.
ARZERRA (ofatumumab) is a human monoclonal antibody. Ig G molecules cross the placenta increasingly after the first trimester. Based on its mechanism of action (B-cell depletion), there is a potential risk of fetal B-cell lymphocytopenia and impaired immune response. Data from animal studies are insufficient. The drug should be avoided during pregnancy unless the benefit clearly outweighs the risk.
Pregnancy Category D. Positive evidence of human fetal risk. Based on its mechanism of action (m TOR inhibitor) and animal studies, AFINITOR (everolimus) is embryotoxic and fetotoxic. First trimester exposure carries risk of structural anomalies; second and third trimester exposure may cause fetal growth restriction, oligohydramnios, and renal impairment. Use only if benefit outweighs risk.
It is unknown whether ofatumumab is excreted in human milk. Human Ig G is present in breast milk, but levels are low. Due to the potential for serious adverse reactions in the breastfed infant (including B-cell depletion), breastfeeding is not recommended during therapy and for at least 6 months after the last dose. No M/P ratio is available.
No data on presence in human milk, effects on breastfed infant, or milk production. M/P ratio unknown. Breastfeeding is not recommended due to potential adverse effects on the developing immune system and growth.
No specific dose adjustment guidelines are established for pregnancy. The pharmacokinetics of monoclonal antibodies may be altered due to increased plasma volume and clearance in pregnancy, but no formal studies have been conducted. Use caution and consider therapeutic drug monitoring if available.
No specific dose adjustments established for pregnancy. Pharmacokinetic changes in pregnancy (increased volume of distribution, altered hepatic metabolism) may reduce drug exposure; however, given the teratogenic risk, use during pregnancy should be avoided. If unavoidable, consider therapeutic drug monitoring if available and adjust dose to achieve target trough concentrations (typically 3-8 ng/m L for transplant indications; for oncology, refer to specific protocol).
ARZERRA (ofatumumab) is a monoclonal antibody targeting CD20 used in relapsing multiple sclerosis. First dose reactions are common; premedicate with corticosteroids, antihistamines, and antipyretics. Monitor for infections, especially hepatitis B reactivation. Contraindicated in active hepatitis B. Administer as subcutaneous injection; injection site reactions frequent. Live vaccines contraindicated during and after treatment until immune reconstitution.
Monitor renal function and blood glucose regularly; Afinitor (everolimus) can cause non-infectious pneumonitis, so obtain baseline chest imaging and assess for new or worsening respiratory symptoms. Adjust dose for moderate hepatic impairment (Child-Pugh B). Avoid live vaccines during treatment.
Report any signs of infection (fever, chills, cough, painful urination) promptly.,Inform your doctor of any history of hepatitis B infection.,You will receive premedication before the first dose to reduce allergic reactions.,Do not receive live vaccines during treatment or until your doctor confirms immune recovery.,Common side effects include injection site reactions, headache, and fever.,ARZERRA is given as an injection under the skin; rotation of injection sites is recommended.
Take Afinitor at the same time each day, consistently either with or without food.,Avoid grapefruit, grapefruit juice, and Seville oranges during treatment.,Report any new or worsening cough, chest pain, or difficulty breathing immediately.,Monitor for signs of infection such as fever, chills, or sore throat; avoid large crowds and sick individuals.,Use effective contraception during treatment and for 8 weeks after stopping.,Do not crush or chew tablets; swallow whole with a glass of water.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ARZERRA vs AFINITOR, answered by our medical review team.
ARZERRA is a Antineoplastic, Monoclonal Antibody that works by Ofatumumab is a fully human monoclonal antibody that binds specifically to the CD20 molecule on B lymphocytes, resulting in complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC) of CD20+ cells.. AFINITOR is a mTOR Inhibitor Antineoplastic that works by Inhibitor of mammalian target of rapamycin (m TOR), specifically the m TORC1 complex, by binding to the FKBP-12 protein, reducing cell proliferation, angiogenesis, and glucose uptake.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ARZERRA and AFINITOR depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ARZERRA is: ARZERRA (ofatumumab) for chronic lymphocytic leukemia (CLL): Initial dose 300 mg IV, then 1 week later 2000 mg IV weekly for 6 doses, then 2000 mg IV every 4 weeks for up to 4 additional doses. For relapsed CLL: 300 mg IV followed by 1000 mg IV on day 8, then 1000 mg IV on day 15 and day 22 of cycle 1, then 1000 mg IV on day 1 of cycles 2-6 (28-day cycles). Premedicate with acetaminophen, antihistamine, and corticosteroid.. The standard adult dose of AFINITOR is: 10 mg orally once daily for advanced breast cancer, neuroendocrine tumors, and renal cell carcinoma; 10 mg orally once daily for subependymal giant cell astrocytoma (SEGA) in adults; 5 mg/m^2 orally once daily for SEGA in pediatric patients (titrated to trough levels 5-15 ng/m L).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ARZERRA and AFINITOR in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ARZERRA is classified as Category C. ARZERRA (ofatumumab) is a human monoclonal antibody. IgG molecules cross the placenta increasingly after the first trimester. Based on its mechanism of action (B-cell depletion), t. AFINITOR is classified as Category C. Pregnancy Category D. Positive evidence of human fetal risk. Based on its mechanism of action (mTOR inhibitor) and animal studies, AFINITOR (everolimus) is embryotoxic and fetotoxi. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.